TGTX Earnings Prediction
The chart below shows how TGTX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TGTX sees a -3.35% change in stock price 10 days leading up to the earnings, and a +4.31% change 10 days following the report. On the earnings day itself, the stock moves by +14.28%. This data can give you a slight idea of what to expect for the next quarter's release.
TGTX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
83.88M
-49.41%
14.17%
Gross Margin
88.86%
-9.22%
0.18%
Operating Margin
14.82%
-78.59%
23.50%
Net Margin
4.63%
-93.26%
-50.53%
EPS
0.02
-97.26%
-50.00%
No Data Available
TGTX Earnings Analysis
TG Therapeutics, Inc. Corporation (TGTX.O) Earnings Conference Call
Positive
Third Quarter Net Sales: B R I U M V I third quarter U S net sales were $83.3 million.
Record Sales Growth: We achieved second quarter net sales of $83.3 million, reflecting approximately 15% quarter-over-quarter growth and over 230% growth from the same quarter last year, solidifying B R I U M V I as the fastest-growing DMT in the U S MS market.
Net Income Achievement: We generated net income in both the three and nine months ending September 2024, with our GAAP net income approximately $3.9 million or $0.02 per diluted share.
Net Income Overview: Our GAAP net income was approximately $3.9 million or $0.02 per diluted share, and when excluding non-cash items, net income for the three month period was approximately $15.7 million.
Cash and Investments Overview: We ended the third quarter with approximately $341 million in cash, cash equivalents and investment securities.
Negative
Net Sales Decline: B R I U M V I third quarter net sales were $83.3 million, reflecting a decrease from the previous quarter.
Net Income Decline: Our GAAP net income was approximately $3.9 million or $0.02 per diluted share, indicating a decline in profitability.
Operating Expense Forecast: Our OpEx for the first nine months of 2024 is approximately $155 million, and we expect our OpEx to come in well below the guidance of approximately $250 million for the full year.
Summer Patient Visit Trends: We observed some expected summer dynamics in the third quarter, where new patient visits tend to slow, impacting overall growth.
Cash Position Analysis: We ended the third quarter with approximately $341 million in cash, which is lower than anticipated for our operational needs.
TGTX FAQs
How does TGTX typically perform around its earnings report dates?
Is TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TGTX Earning Call Sentiment
TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TGTX.O
-1.54%Positive
The company reported strong financial performance, with significant growth in BRIUMVI sales and raised revenue guidance. They have a solid cash position and a share repurchase program, both positive indicators. The Q&A revealed no major concerns, and analysts were generally positive. The company is addressing supply chain risks and competitive pressures effectively. Overall, the positive financial metrics, strategic initiatives, and optimistic guidance suggest a positive stock price movement.
